LP
ASBPW

LMR Partners’s Aspire Biopharma Warrant ASBPW Stock Holding History

LMR Partners’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-125,000
Closed -$5.29K – 1688
2024
Q3 		$5.29K Buy
+125,000
New +$5.95K ﹤0.01% 1178

Other funds holding ASBPW

MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's ASBPW Position: Q1 2026 in Review

LMR Partners held its Aspire Biopharma Warrant (ASBPW) position steady in Q1 2026 at 125,000 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

LMR Partners first reported a position in ASBPW in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.31M in Q1 2023. 29 funds tracked by Wall St. Rank hold ASBPW as of Q1 2026.

  • LMR Partners held 125,000 shares of Aspire Biopharma Warrant worth $2.08K as of Q1 2026.
  • LMR Partners left its Aspire Biopharma Warrant share count unchanged in Q1 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1402 holding.
  • LMR Partners first reported a position in Aspire Biopharma Warrant in Q4 2022 and has held it in 13 quarters since.
  • LMR Partners's Aspire Biopharma Warrant position peaked at $1.31M in Q1 2023.
  • 29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.